Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | GHSR | Q92847 | 2/20 | 0.43 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | BRD1 | O95696 | 1/20 | 0.42 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2470496 | 0.86 | ADRB2 (0.57) | ADRB2ADRB1ADRB3MAPTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4915819 | 0.85 | ADRB2 (0.56) | ADRB2ADRB1ADRB3MAPTSMN1; SMN2 | |
| SCHEMBL2474733 | 0.80 | HTR6 (0.47) | HTR6IKBKBGPR119CYP19A1 | |
| SCHEMBL3556924 | 0.75 | SLC2A1 (0.52) | HTR6SLC2A1MAPTIKBKB | |
| SCHEMBL1718081 | 0.75 | DRD3 (0.42) | ADRB2ADRB1ADRB3MAPTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4922945 | 0.74 | DRD3 (0.42) | ADRB2ADRB1ADRB3MAPTSMN1; SMN2 | |
| SCHEMBL3561071 | 0.72 | HTR6 (0.51) | HTR6SLC2A1MAPT | |
| SCHEMBL31681359 | 0.72 | LMNA (0.58) | HTR6MAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL23988635 | 0.71 | BTK (0.52) | MAPTSMN1; SMN2ALDH1A1LMNAPKM | |
| SCHEMBL2470132 | 0.71 | ALDH1A1 (0.44) | ADRB3MAPTSMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220635-A1 | AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-08-30 | — | — | US | disclosed |
| US-8232426-B2 | N-[4-((S)-2-Propylamino-propyl)-phenyl]-4-trifluoromethoxy-benzenesulfonamide; Dipropyl-{2-[4-(4-trifluoromethoxy-benzenesulfonylmethyl)-phenyl]-ethyl}-dipropyl-amine salt, psychological, nervous system disorders such as schizophernia, bipolar, dyskinesias, tourette syndrome, depression, sleep disorder | ABBOTT GMBH & CO. KG (DE) | 2012-07-31 | — | — | US | disclosed |
| EP-2371814-A1 | Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | Abbott GmbH & Co. KG (DE) | 2011-10-05 | — | — | EP | disclosed |
| US-20080096934-A1 | Aminoethylaromatic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | ABBOTT GMBH & CO. KG (DE) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096934-A1 | Aminoethylaromatic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | MC3R, DRD3, ADORA3 | HTR6 56/4885SLC2A1 1626/4885ADRB2 57/4885 |
| US-20120220635-A1 | AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | SLC6A3, ADRB3, DRD3 | HTR6 72/4885SLC2A1 1635/4885ADRB2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.